E. Oger, Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale, Thromb Haemost, vol.83, pp.657-660, 2000.
URL : https://hal.archives-ouvertes.fr/hal-00726218

J. L. Bosson, D. Pouchain, and J. F. Bergmann, A prospective observational study of a cohort of outpatients with an acute medical event and reduced mobility: incidence of symptomatic thromboembolism and description of thromboprophylaxis practices, Journal of Internal Medicine, vol.91, issue.24, pp.168-176, 2006.
DOI : 10.1007/s11239-004-0208-6

URL : https://hal.archives-ouvertes.fr/hal-00281342

J. Blom, C. Doggen, and S. Osanto, Malignancies, Prothrombotic Mutations, and the Risk of Venous Thrombosis, JAMA, vol.293, issue.6, pp.715-722, 2005.
DOI : 10.1001/jama.293.6.715

A. Trousseau, Phlegmasia alba dolens In: Clinique medicale d'Hotel-Dieu de Paris, Paris: JB Balliere et Fils, pp.1865-654

F. Rickles and A. Falanga, Molecular Basis for the Relationship Between Thrombosis and Cancer, Thrombosis Research, vol.102, issue.6, pp.215-239, 2001.
DOI : 10.1016/S0049-3848(01)00285-7

J. Zwicker, B. Furie, and B. Furie, Cancer-associated thrombosis, Critical Reviews in Oncology/Hematology, vol.62, issue.2, pp.126-162, 2007.
DOI : 10.1016/j.critrevonc.2007.01.001

M. De-cicco, The prothrombotic state in cancer: pathogenic mechanisms, Critical Reviews in Oncology/Hematology, vol.50, issue.3, pp.87-196, 2004.
DOI : 10.1016/j.critrevonc.2003.10.003

I. Elalamy, Physiopathog??nie de la maladie thromboembolique veineuse au cours du cancer, Pathologie Biologie, vol.56, issue.4, pp.184-94, 2008.
DOI : 10.1016/j.patbio.2008.03.003

A. Falanga and L. Zacharski, Deep vein thrombosis in cancer: the scale of the problem and approaches to management, Annals of Oncology, vol.16, issue.5, pp.696-701, 2005.
DOI : 10.1093/annonc/mdi165

A. Falanga, T. Barbui, and F. Rickles, Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis, Thromb Haemost, vol.70, issue.3, pp.540-542, 1993.

C. Ay, R. Vormittag, and D. Dunkler, D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study, Journal of Clinical Oncology, vol.27, issue.25, pp.4124-4133, 2009.
DOI : 10.1200/JCO.2008.21.7752

L. Knowlson, S. Bacchu, and S. Paneesha, Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism, Journal of Clinical Pathology, vol.63, issue.9, pp.818-840, 2010.
DOI : 10.1136/jcp.2010.076349

M. Gunter, R. Stolzenberg-solomon, and A. Cross, A Prospective Study of Serum C-Reactive Protein and Colorectal Cancer Risk in Men, Cancer Research, vol.66, issue.4, pp.2483-2490, 2006.
DOI : 10.1158/0008-5472.CAN-05-3631

E. Fox and S. Kahn, The relationship between inflammation and venous thrombosis. A systematic review of clinical studies, Thrombosis and Haemostasis, vol.94, pp.362-367, 2005.
DOI : 10.1160/TH05-04-0266

P. Mannucci, M. Karimi, A. Mosalaei, M. Canciani, and F. Peyvandi, Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease), Haematologica, vol.88, pp.454-462, 2003.

V. Jimenez-zepeda and V. Dominguez-martinez, Acquired activated protein C resistance and thrombosis in multiple myeloma patients, Thromb J, vol.4, p.11, 2006.

K. Woollard, SOLUBLE BIO-MARKERS IN VASCULAR DISEASE: MUCH MORE THAN GAUGES OF DISEASE?, Clinical and Experimental Pharmacology and Physiology, vol.249, issue.4, pp.233-273, 2005.
DOI : 10.1038/nm899

R. Ludwig, S. Alban, and R. Bistrian, The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo, Thrombosis and Haemostasis, vol.95, pp.535-575, 2006.
DOI : 10.1160/TH05-07-0515

J. Yu, L. May, and V. Lhotak, Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis, Blood, vol.105, issue.4, pp.1734-1775, 2005.
DOI : 10.1182/blood-2004-05-2042

W. Ruf, Tissue factor and PAR signaling in tumor progression, Thrombosis Research, vol.120, pp.7-12, 2007.
DOI : 10.1016/S0049-3848(07)70125-1

M. Durand, J. Bodker, and A. Christensen, Plasminogen-Activator Inhibitor-I and tumor growth, invasion, and metastasis, Thromb Haemost, vol.91, pp.438-487, 2004.

Z. Mallat, H. Benamer, and B. Hugel, Elevated Levels of Shed Membrane Microparticles With Procoagulant Potential in the Peripheral Circulating Blood of Patients With Acute Coronary Syndromes, Circulation, vol.101, issue.8, pp.841-844, 2000.
DOI : 10.1161/01.CIR.101.8.841

M. Vanwijk, R. Nieuwland, and K. Boer, Microparticle subpopulations are increased in preeclampsia: Possible involvement in vascular dysfunction?, American Journal of Obstetrics and Gynecology, vol.187, issue.2, pp.450-456, 2002.
DOI : 10.1067/mob.2002.124279

R. Nieuwland, R. Berckmans, and S. Mcgregor, Cellular origin and procoagulant properties of microparticles in meningococcal sepsis, Blood, vol.95, pp.930-935, 2000.

F. Sabatier, P. Darmon, and B. Hugel, Type 1 And Type 2 Diabetic Patients Display Different Patterns of Cellular Microparticles, Diabetes, vol.51, issue.9, pp.2840-2845, 2002.
DOI : 10.2337/diabetes.51.9.2840

A. Leroyer, A. Tedgui, and C. Boulanger, Role of microparticles in atherothrombosis, Journal of Internal Medicine, vol.89, issue.5, pp.528-565, 2008.
DOI : 10.1046/j.1365-2141.2003.04716.x

R. Zwaal and A. Schroit, Pathophysiologic implications of membrane phospholipid asymmetry in blood cells, Blood, vol.89, pp.1121-1153, 1997.

H. Kim, K. Song, and Y. Park, Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor, European Journal of Cancer, vol.39, issue.2, pp.184-91, 2003.
DOI : 10.1016/S0959-8049(02)00596-8

P. Jurasz, D. Alonso-ecolano, and M. Radomski, Platelet-cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation, British Journal of Pharmacology, vol.170, issue.7, pp.819-845, 2004.
DOI : 10.1038/sj.bjp.0706013

J. Palumbo and J. Degen, Mechanisms linking tumor cell-associated procoagulant function to tumor metastasis, Thrombosis Research, vol.120, pp.22-30, 2007.
DOI : 10.1016/S0049-3848(07)70127-5

A. Lee, The Thrombophilic State Induced by Therapeutic Agents in the Cancer Patient, Seminars in Thrombosis and Hemostasis, vol.25, issue.02, pp.137-145, 1999.
DOI : 10.1055/s-2007-994915

H. Otten, J. Mathijssen, T. Cate, and H. , Symptomatic Venous Thromboembolism in Cancer Patients Treated With Chemotherapy, Archives of Internal Medicine, vol.164, issue.2, pp.190-194, 2004.
DOI : 10.1001/archinte.164.2.190

B. Fisher, J. Costantino, and C. Redmond, A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor???Positive Tumors, New England Journal of Medicine, vol.320, issue.8, pp.479-484, 1989.
DOI : 10.1056/NEJM198902233200802

K. Pritchard, A. Paterson, and N. Paul, Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group., Journal of Clinical Oncology, vol.14, issue.10, pp.2731-2737, 1996.
DOI : 10.1200/JCO.1996.14.10.2731

S. Nalluri, D. Chu, and R. Keresztes, Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients, JAMA, vol.300, issue.19, pp.2277-85, 2008.
DOI : 10.1001/jama.2008.656

A. Khorana, C. Francis, and E. Culakova, Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients, Cancer, vol.119, issue.10, pp.2339-2385, 2007.
DOI : 10.1002/cncr.23062

A. Khorana, C. Francis, and E. Culakova, Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy, Journal of Thrombosis and Haemostasis, vol.17, issue.3, pp.632-636, 2007.
DOI : 10.1111/j.1538-7836.2007.02374.x

M. Levine, M. Gent, and J. Hirsh, The Thrombogenic Effect of Anticancer Drug Therapy in Women with Stage II Breast Cancer, New England Journal of Medicine, vol.318, issue.7, pp.404-411, 1988.
DOI : 10.1056/NEJM198802183180703

M. Elliott, R. Wolf, and C. Hook, Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin, Leukemia & Lymphoma, vol.12, issue.5, pp.1545-1549, 2004.
DOI : 10.1080/08880010050211376

M. Zangari, E. Anaissie, and B. Barlogie, Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy, Blood, vol.98, issue.5, pp.1614-1615, 2001.
DOI : 10.1182/blood.V98.5.1614

S. Menon, S. Rajkumar, and M. Lacy, Thromboembolic events with lenalidomide-based therapy for multiple myeloma, Cancer, vol.108, issue.7, pp.1522-1530, 2008.
DOI : 10.1002/cncr.23336

E. Accaoui, R. Shamseddeen, W. Taher, and A. , Thalidomide and thrombosis: a meta-analysis, Thrombosis and Haemostasis, vol.97, issue.6, pp.1031-1037, 2007.
DOI : 10.1160/TH06-09-0494

C. Bennett, C. Angelotta, and P. Yarnold, Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer, JAMA, vol.296, issue.21, pp.2558-60, 2006.
DOI : 10.1001/jama.296.21.2558-c

F. Scappaticci, J. Skillings, and S. Holden, Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab, JNCI Journal of the National Cancer Institute, vol.99, issue.16, pp.1232-1241, 2007.
DOI : 10.1093/jnci/djm086

L. Junck, Bevacizumab antiangiogenic therapy for glioblastoma, Neurology, vol.76, issue.5, pp.414-419, 2011.
DOI : 10.1212/WNL.0b013e31820a0d7e

J. Bohlius, J. Wilson, and J. Seidenfeld, Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients, JNCI Journal of the National Cancer Institute, vol.98, issue.10, pp.708-714, 2006.
DOI : 10.1093/jnci/djj189

A. C. Matzdorff, Management of venous thromboembolism in cancer patients, Reviews in Vascular Medicine, vol.2, issue.1, pp.24-36, 2014.
DOI : 10.1016/j.rvm.2013.10.005

R. Ahkhan, A. Coben, and S. Combe, Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the Medenox Study, Arch Intern Med, vol.164, issue.9, pp.963-971, 2004.

J. Heit, M. Silverstein, and D. Mohr, Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism, Archives of Internal Medicine, vol.160, issue.6, pp.809-824, 2000.
DOI : 10.1001/archinte.160.6.809

J. Heit, O. Fallon, W. Petterson, and T. , Relative Impact of Risk Factors for Deep Vein Thrombosis and Pulmonary Embolism, Archives of Internal Medicine, vol.162, issue.11, pp.1245-1253, 2002.
DOI : 10.1001/archinte.162.11.1245

R. Wolf, Are patients with cancer receiving adequate thromboprophylaxis? Results from FRONTLINE, Cancer Treatment Reviews, vol.29, issue.2, pp.7-9, 2003.
DOI : 10.1016/S0305-7372(03)80002-6

C. Kirwan, Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey, BMJ, vol.327, issue.7415, pp.597-598, 2003.
DOI : 10.1136/bmj.327.7415.597

M. Johnson, M. Sproule, and J. Paul, The Prevalence and Associated Variables of Deep Venous Thrombosis in Patients with Advanced Cancer, Clinical Oncology, vol.11, issue.2, pp.105-110, 1999.
DOI : 10.1053/clon.1999.9023

E. Sproul, Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis, Am J Cancer, vol.34, pp.566-85, 1938.

J. Ambrus, C. Ambrus, and I. Mink, Causes of death in cancer patients, J Med, vol.6, pp.61-64, 1975.

H. Chew, T. Wun, and D. Harvey, Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers, Archives of Internal Medicine, vol.166, issue.4, pp.458-64, 2006.
DOI : 10.1001/archinte.166.4.458

M. Donati, Cancer and Thrombosis, Pathophysiology of Haemostasis and Thrombosis, vol.24, issue.2, pp.128-131, 1994.
DOI : 10.1159/000217092

A. A. Khorana, C. W. Francis, and E. Culakova, Thromboembolism in Hospitalized Neutropenic Cancer Patients, Journal of Clinical Oncology, vol.24, issue.3, pp.484-490, 2006.
DOI : 10.1200/JCO.2005.03.8877

H. Sorensen, L. Mellemkjaer, and J. Olsen, Prognosis of Cancers Associated with Venous Thromboembolism, New England Journal of Medicine, vol.343, issue.25, pp.1846-1850, 2000.
DOI : 10.1056/NEJM200012213432504

N. Levitan, A. Dowlati, and S. Remick, Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data, Medicine, vol.78, issue.5, pp.285-291, 1999.
DOI : 10.1097/00005792-199909000-00001

P. Prandoni, A. Lensing, and A. Piccioli, Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis, Blood, vol.100, issue.10, pp.3484-3488, 2002.
DOI : 10.1182/blood-2002-01-0108

S. Laporte, P. Mismetti, and H. Decousus, Clinical Predictors for Fatal Pulmonary Embolism in 15 520 Patients With Venous Thromboembolism: Findings From the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry, Circulation, vol.117, issue.13, pp.1711-1717, 2008.
DOI : 10.1161/CIRCULATIONAHA.107.726232

URL : https://hal.archives-ouvertes.fr/ujm-00439761

E. J. Rance and C. Guedj, Occult cancer in patients with bilateral deep-vein thrombosis, The Lancet, vol.350, issue.9089, pp.1448-1457, 1997.
DOI : 10.1016/S0140-6736(05)64210-9

A. Bura, N. Cailleux, and B. Bienvenu, Incidence and prognosis of cancer associated with bilateral venous thrombosis: a prospective study of 103 patients, Journal of Thrombosis and Haemostasis, vol.67, issue.3, pp.441-445, 2004.
DOI : 10.1056/NEJM200012213432504

B. Hutten, M. Prins, and M. Gent, Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis, Journal of Clinical Oncology, vol.18, issue.17, pp.3078-83, 2000.
DOI : 10.1200/JCO.2000.18.17.3078

I. Martinelli, D. Stefano, and V. , Rare thromboses of cerebral, splanchnic and upper-extremity veins, Thrombosis and Haemostasis, vol.103, issue.6, pp.1136-1144, 2010.
DOI : 10.1160/TH09-12-0873

R. White, Targeting patients for anticoagulant prophylaxis trials in patients with cancer: Who is at highest risk? Thrombosis Research, pp.29-40, 2007.

S. Sallah, J. Wan, and N. Nguyen, Venous thrombosis in patients with solid tumors: determination of frequency and characteristics, Thromb Haemost, vol.87, issue.4, pp.575-584, 2002.

J. Trujillo-santos, A. Ruiz-gamietea, and J. Luque, Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Findings from the RIETE Registry, Thrombosis Research, vol.123, pp.10-15, 2009.
DOI : 10.1016/S0049-3848(09)70003-9

D. Bergqvist, J. Caprini, and O. Dotsenko, Venous Thromboembolism and Cancer, Current Problems in Surgery, vol.44, issue.3, pp.157-216, 2007.
DOI : 10.1067/j.cpsurg.2007.01.004

F. De-lorenzo, O. Dotsenko, and M. Scully, The Role of Anticoagulation in Cancer Patients: Facts and Figures, Anti-Cancer Agents in Medicinal Chemistry, vol.6, issue.6, pp.579-87, 2006.
DOI : 10.2174/187152006778699112

J. Lin, Risk factors associated with venous thromboembolic events in patients with malignancy, Blood Coagulation & Fibrinolysis, pp.265-270, 2006.

G. Lyman, A. Khorana, and N. Kuderer, Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, Journal of Clinical Oncology, vol.31, issue.17, pp.2189-204, 2013.
DOI : 10.1200/JCO.2013.49.1118

S. Rhodes, A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism, European Journal of Oncology Nursing, vol.12, issue.5, pp.425-429, 2008.
DOI : 10.1016/j.ejon.2008.08.001

A. Khorana, N. Kuderer, and E. Culakova, Development and validation of a predictive model for chemotherapy-associated thrombosis, Blood, vol.111, issue.10, pp.4902-4909, 2008.
DOI : 10.1182/blood-2007-10-116327

A. Khorana, K. Herman, and D. Rubens, A predictive risk score for cancer associated thrombosis: Role of screening in a prospective study, Blood (ASH Annual Meeting Abstracts), vol.119, p.3173, 2010.

D. George, G. Agnelli, and W. Fisher, Venous Thromboembolism (VTE) Prevention with Semuloparin in Cancer Patients Initiating Chemotherapy: Benefit-Risk Assessment by VTE Risk in SAVE-ONCO, Blood (ASH Annual Meeting Abstracts), vol.118, p.206, 2011.

R. Moore, A. N. Riedel, and E. , High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis, Journal of Clinical Oncology, vol.29, issue.25, pp.3466-73, 2011.
DOI : 10.1200/JCO.2011.35.5669

M. Mandala, M. Clerici, and I. Corradino, Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience', Annals of Oncology, vol.23, issue.6, pp.1416-1437, 2012.
DOI : 10.1093/annonc/mdr524

C. Ay, D. Dunkler, and C. Marosi, Prediction of venous thromboembolism in cancer patients, Blood, vol.116, issue.24, pp.5377-82, 2013.
DOI : 10.1182/blood-2010-02-270116

A. Khorana, The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients, The Oncologist, vol.12, issue.11, pp.1361-70, 2007.
DOI : 10.1634/theoncologist.12-11-1361

D. Farge, L. Bosquet, and D. Kassab-chahmi, 2008 french national guidelines for the treatment of venous thromboembolism in patients with cancer: Report from the working group, Critical Reviews in Oncology/Hematology, vol.73, issue.1, pp.31-46, 2008.
DOI : 10.1016/j.critrevonc.2008.12.004

URL : https://hal.archives-ouvertes.fr/ujm-00439710

M. Mandala, A. Falanga, and A. Piccioli, Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM), Critical Reviews in Oncology/Hematology, vol.59, issue.3, pp.194-204, 2006.
DOI : 10.1016/j.critrevonc.2006.05.001

M. Mandala, A. Falanga, and F. Roila, On behalf of the ESMO Guidelines Working Group Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.22, pp.85-92, 2011.

S. Kahn, W. Lim, and A. Dunn, Prevention of VTE in Nonsurgical Patients, Chest, vol.141, issue.2, pp.195-226, 2012.
DOI : 10.1378/chest.11-2296

M. Scully, W. Geerts, and M. Kovacs, Clinical guide: cancer and thrombosis. The Thrombosis Interest Group of Canada Available from http, Thrombosis Interest Group of Canada recommendations23, 2010.

A. Kakkar and R. Williamson, Prevention of Venous Thromboembolism in Cancer Patients, Seminars in Thrombosis and Hemostasis, vol.25, issue.02, pp.239-282, 1999.
DOI : 10.1055/s-2007-994925

A. Kakkar, S. Haas, and H. Wolf, Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients. The MC-4 cancer substudy, Thrombosis and Haemostasis, vol.94, issue.4, pp.867-71, 2005.
DOI : 10.1160/TH04-03-0189

O. Huber, H. Bounameaux, and F. Borst, Postoperative Pulmonary Embolism After Hospital Discharge, Archives of Surgery, vol.127, issue.3, pp.310-313, 1992.
DOI : 10.1001/archsurg.1992.01420030076014

D. Bergqvist, G. Agnelli, and A. Cohen, Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer, New England Journal of Medicine, vol.346, issue.13, pp.975-980, 2002.
DOI : 10.1056/NEJMoa012385

G. Agnelli, G. Bolis, and L. Capussotti, A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery, Annals of Surgery, vol.243, issue.1, pp.89-95, 2006.
DOI : 10.1097/01.sla.0000193959.44677.48

D. Clarke-pearson, I. Synan, and W. Creasman, Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy, American Journal of Obstetrics and Gynecology, vol.147, issue.4, pp.369-75, 1983.
DOI : 10.1016/S0002-9378(16)32227-X

M. Martino, E. Borges, and E. Williamson, Pulmonary Embolism After Major Abdominal Surgery in Gynecologic Oncology, Obstetrics & Gynecology, vol.107, issue.3, pp.666-71, 2006.
DOI : 10.1097/01.AOG.0000200046.28199.ae

G. Clagett and J. Reisch, Prevention of Venous Thromboembolism in General Surgical Patients, Annals of Surgery, vol.208, issue.2, pp.227-267, 1988.
DOI : 10.1097/00000658-198808000-00016

. Enoxacan-study and . Group, Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment, British Journal of Surgery, vol.84, issue.8
DOI : 10.1046/j.1365-2168.1997.d01-3882.x

D. Bergqvist, U. Burmark, and P. Flordal, Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500versus 5000 Xal units in 2070 patients, British Journal of Surgery, vol.318, issue.4, pp.496-501, 1995.
DOI : 10.1002/bjs.1800820421

A. Liezorovicz, H. Picolet, and J. Peyrieux, Prevention of perioperative deep vein thrombosis in general surgery: A multicentre double blind study comparing two doses of Logiparin and standard heparin, British Journal of Surgery, vol.78, issue.4, pp.412-418, 1991.
DOI : 10.1002/bjs.1800780410

V. Kakkar, A. Cohen, and R. Edmonson, Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery, The Lancet, vol.341, issue.8840, pp.259-65, 1993.
DOI : 10.1016/0140-6736(93)92614-Y

P. Mismetti, S. Laporte-simitsidis, and B. Tardy, Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials, Thromb Haemost, vol.83, issue.1, pp.14-23, 2000.

M. Leonardi, A Systematic Review of Deep Venous Thrombosis Prophylaxis in Cancer Patients: Implications for Improving Quality, Annals of Surgical Oncology, vol.126, issue.Suppl 1, pp.929-936, 2007.
DOI : 10.1245/s10434-006-9183-9

M. Rasmussen, Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis, Cancer Treatment Reviews, vol.28, issue.3, pp.141-144, 2002.
DOI : 10.1016/S0305-7372(02)00043-9

V. Kakkar, J. Balibrea, and J. Martinez-gonzalez, Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study, Journal of Thrombosis and Haemostasis, vol.100, issue.6, pp.1223-1232, 2010.
DOI : 10.1111/j.1538-7836.2010.03892.x

R. Bona, Thrombotic Complications of Central Venous Catheters in Cancer Patients, Seminars in Thrombosis and Hemostasis, vol.25, issue.02, pp.147-155, 1999.
DOI : 10.1055/s-2007-994916

M. Verso, G. Agnelli, and P. Kamphuisen, Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients, Internal and Emergency Medicine, vol.18, issue.2, pp.117-139, 2008.
DOI : 10.1007/s11739-008-0125-3

W. Saber, T. Moua, and E. Williams, Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies, Journal of Thrombosis and Haemostasis, vol.15, issue.2, pp.312-321, 2011.
DOI : 10.1111/j.1538-7836.2010.04126.x

M. Bern, J. Lokich, and S. Wallach, Very Low Doses of Warfarin Can Prevent Thrombosis in Central Venous Catheters, Annals of Internal Medicine, vol.112, issue.6, pp.423-428, 1990.
DOI : 10.7326/0003-4819-76-3-112-6-423

D. Heaton, D. Han, and A. Inder, Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis, Internal Medicine Journal, vol.32, issue.3, pp.84-88, 2002.
DOI : 10.1046/j.1445-5994.2002.00171.x

M. Monreal, A. Alastrue, and M. Rull, Upper extremity deep venous thrombosis in cancer patients with venous access devices: prophylaxis with a low molecular weight heparin (Fragmin), Thromb Haemost, vol.75, pp.251-253, 1996.

P. Chaukiyal, A. Nautiyal, and S. Radhakrishnan, Thromboprophylaxis in cancer patients with central venous catheters. A systematic review and meta-analysis, Thrombosis and Haemostasis, vol.99, issue.1, pp.38-43, 2008.
DOI : 10.1160/TH07-07-0446

M. Cunningham, B. White, and D. Hollywood, Primary thromboprophylaxis for cancer patients with central venous catheters ??? a reappraisal of the evidence, British Journal of Cancer, vol.295, issue.2, pp.189-94, 2006.
DOI : 10.1200/JCO.2005.06.084

A. Chan, A. Iannucci, and W. Dager, Systemic Anticoagulant Prophylaxis for Central Catheter???Associated Venous Thrombosis in Cancer Patients, Annals of Pharmacotherapy, vol.26, issue.4, pp.635-676, 2007.
DOI : 10.1345/aph.1G714

M. Carrier, J. Tay, and D. Fergusson, Thromboprophylaxis for catheter-related thrombosis in patients with cancer: a systematic review of the randomized, controlled trials, Journal of Thrombosis and Haemostasis, vol.18, issue.12, pp.2552-2556, 2007.
DOI : 10.1111/j.1538-7836.2007.02751.x

D. Farge, C. Durant, and S. Villiers, Lessons from French national guidelines on the treatment of venous thrombosis and central venous catheter thrombosis in cancer patients, Thrombosis Research, vol.125, pp.108-124, 2010.
DOI : 10.1016/S0049-3848(10)70027-X

S. Smorenburg, R. Hettiarachchi, and R. Vink, The effects of unfractionated heparin on survival in patients with malignancye a systematic review, Thromb Haemost, vol.82, pp.1600-1604, 1999.

N. Lemoine, Antithrombotic therapy in cancer:2119e2. 71 Falanga A. The effect of anticoagulant drugs on cancer, J Clin Oncol J Thromb Haemost, vol.232, pp.1263-1265, 2004.

K. Sideras, P. Schaefer, and S. Okuno, Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial, Mayo Clinic Proceedings, vol.81, issue.6, pp.758-67, 2006.
DOI : 10.4065/81.6.758

A. Lazo-langner, G. Goss, and J. Spaans, The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials, Journal of Thrombosis and Haemostasis, vol.3, issue.1, pp.729-737, 2007.
DOI : 10.1016/S0140-6736(00)04337-3

S. Haas, S. Schellong, and U. Tebbe, Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY, BMC Cancer, vol.50, issue.2, p.316, 2011.
DOI : 10.1002/bimj.200710410

D. Garcia, T. Baglin, and J. Weitz, Parenteral Anticoagulants, Chest, vol.141, issue.2, pp.24-43, 2012.
DOI : 10.1378/chest.11-2291

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278070

E. Gray, B. Mulloy, and T. Barrowcliffe, Heparin and low-molecularweight heparin, Thrombosis and Haemostasis, vol.99, pp.807-825, 2008.

S. Shaughnessy, E. Young, and P. Deschamps, The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria, Blood, vol.86, pp.1368-73, 1995.

L. Linkins, A. Dans, and L. Moores, Treatment and Prevention of Heparin-Induced Thrombocytopenia, Chest, vol.141, issue.2, pp.495-530, 2012.
DOI : 10.1378/chest.11-2303

N. Martel, J. Lee, and P. Wells, Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis, Blood, vol.106, issue.8, pp.2710-2715, 2005.
DOI : 10.1182/blood-2005-04-1546

W. Ageno, R. Grimwood, and S. Limbiati, Hometreatment of deep vein thrombosis in patients with cancer, Haematologica, vol.90, issue.2, pp.220-224, 2005.

P. Wells, M. Kovacs, and J. Bormanis, Expanding Eligibility for Outpatient Treatment of Deep Venous Thrombosis and Pulmonary Embolism With Low-Molecular-Weight Heparin, Archives of Internal Medicine, vol.158, issue.16, pp.1809-1821, 1998.
DOI : 10.1001/archinte.158.16.1809

L. Harrison, J. Mcginnis, and M. Crowther, Assessment of Outpatient Treatment of Deep-Vein Thrombosis With Low-Molecular-Weight Heparin, Archives of Internal Medicine, vol.158, issue.18, pp.2001-2004, 1998.
DOI : 10.1001/archinte.158.18.2001

O. Shaughnessy, D. Miles, J. Wimperis, and J. , UK patients with deep-vein thrombosis can be safely treated as out-patients, QJM, vol.93, issue.10, pp.663-670, 2000.
DOI : 10.1093/qjmed/93.10.663

W. Ageno, L. Steidl, and C. Marchesi, Selecting patients for home treatment of deep vein thrombosis: the problem of cancer, Haematologica, vol.87, pp.286-91, 2002.

C. Landefeld, P. Anderson, and L. Goodnough, The bleeding severity index: Validation and comparison to other methods for classifying bleeding complications of medical therapy, Journal of Clinical Epidemiology, vol.42, issue.8, pp.711-719, 1989.
DOI : 10.1016/0895-4356(89)90066-8

A. Barbot, Assessing 2-Month Clinical Prognosis in Hospitalized Patients With Advanced Solid Tumors, Journal of Clinical Oncology, vol.26, issue.15, pp.26-2538, 2008.
DOI : 10.1200/JCO.2007.14.9518

G. Lyman, A. Khorana, and A. Falanga, American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer, Journal of Clinical Oncology, vol.25, issue.34, pp.5490-505, 2007.
DOI : 10.1200/JCO.2007.14.1283

C. Weber, T. Merminod, and F. Hermann, Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study, Supportive Care in Cancer, vol.11, issue.7, pp.847-52, 2008.
DOI : 10.1007/s00520-007-0339-3

J. F. Bergmann, Risque thromboembolique veineux et pratique de pr??vention hospitali??re??: r??sultats obtenus en France de l?????tude internationale ENDORSE, La Presse M??dicale, vol.40, issue.12, pp.528-537, 2011.
DOI : 10.1016/j.lpm.2011.06.023

A. Fontaine, Effectiveness of written guidelines on the appropriateness of thromboprophylaxis prescriptions for medical patients: a prospective randomized study, Journal of Internal Medicine, vol.102, issue.2, pp.369-376, 2006.
DOI : 10.1002/ajh.20281

S. Kahn, A. Panju, and W. Geerts, Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada, Thrombosis Research, vol.119, issue.2, pp.145-55, 2007.
DOI : 10.1016/j.thromres.2006.01.011

V. Tapson, H. Decousus, and M. Pini, Venous Thromboembolism Prophylaxis in Acutely Ill Hospitalized Medical Patients, Chest, vol.132, issue.3, pp.936-981, 2007.
DOI : 10.1378/chest.06-2993

URL : https://hal.archives-ouvertes.fr/ujm-00440050

S. A. Ba, A cross-sectional evaluation of venous thromboembolism risk and use of venous thromboembolism prophylaxis in hospitalized patients in Senegal, Archives of Cardiovascular Diseases, vol.104, issue.10, pp.493-501, 2011.
DOI : 10.1016/j.acvd.2011.05.007

L. Lanthier, D. Bechard, and D. Viens, ??valuation de l???utilisation de la thromboprophylaxie chez les patients hospitalis??s dans un centre hospitalier universitaire??: un mod??le applicable d?????valuation de la qualit?? de l???acte. Une revue de 320??patients hospitalis??s, Journal des Maladies Vasculaires, vol.36, issue.1, pp.3-8, 2011.
DOI : 10.1016/j.jmv.2010.10.005

P. Kolodzeike, P. Wille-jorgensen, and . Rasmussen, Inadequate use of prophylaxis against venous thromboembolism in Danish medical departments, Dan Med Bull, vol.58, 2011.

M. Sevestre, Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: The CARMEN study, Journal des Maladies Vasculaires, vol.39, issue.3, pp.161-169, 2014.
DOI : 10.1016/j.jmv.2014.03.001

A. Kakkar, M. Levine, and H. Pinedo, Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey, The Oncologist, vol.8, issue.4, pp.381-389, 2003.
DOI : 10.1634/theoncologist.8-4-381

C. Kalka, D. Spirk, and K. Siebenrock, Lack of extended venous thromboembolism prophylaxis in high-risk patients undergoing major orthopaedic or major cancer surgery. Electronic Assessment of VTE Prophylaxis in High-Risk Surgical Patients at Discharge from Swiss Hospitals (ESSENTIAL), Thrombosis and Haemostasis, vol.102, issue.1, pp.56-61, 2009.
DOI : 10.1160/TH09-02-0097

E. Akl and H. Schünemann, Routine Heparin for Patients with Cancer? One Answer, More Questions, New England Journal of Medicine, vol.366, issue.7, pp.661-663, 2012.
DOI : 10.1056/NEJMe1113672

M. Samama, A. Cohen, and J. Darmon, A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients, New England Journal of Medicine, vol.341, issue.11, pp.793-800, 1999.
DOI : 10.1056/NEJM199909093411103

R. Alikhan, A. Cohen, and S. Combe, Prevention of venous thromboembolism in medical patients with enoxaparin, Blood Coagulation & Fibrinolysis, vol.14, issue.4, pp.341-347, 2003.
DOI : 10.1097/00001721-200306000-00004

B. Zierler, M. Meissner, and K. Cain, A Survey of Physicians' Knowledge and Management of Venous Thromboembolism, Vascular and Endovascular Surgery, vol.36, issue.5, pp.367-375, 2002.
DOI : 10.1177/153857440203600506

S. I. Noble, A. Nelson, and C. Turner, Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study, BMJ, vol.332, issue.7541, pp.577-580, 2006.
DOI : 10.1136/bmj.38733.616065.802

M. Maltoni, A. Caraceni, and C. Brunelli, Prognostic Factors in Advanced Cancer Patients: Evidence-Based Clinical Recommendations???A Study by the Steering Committee of the European Association for Palliative Care, Journal of Clinical Oncology, vol.23, issue.25, pp.6240-6248, 2005.
DOI : 10.1200/JCO.2005.06.866

N. Christakis and E. Lamont, Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study Commentary: Why do doctors overestimate? Commentary: Prognoses should be based on proved indices not intuition, BMJ, vol.320, issue.7233, pp.469-73, 2000.
DOI : 10.1136/bmj.320.7233.469

S. Kahn, T. Ducruet, and D. Lamping, Prospective Evaluation of Health-Related Quality of Life in Patients With Deep Venous Thrombosis, Archives of Internal Medicine, vol.165, issue.10, pp.1173-1181, 2005.
DOI : 10.1001/archinte.165.10.1173

D. Tassarini, C. Santelmo, and E. Scarpi, Controversial Issues in Thromboprophylaxis with Low-Molecular Weight Heparins in Palliative Care, Journal of Pain and Symptom Management, vol.36, issue.2, pp.3-4, 2008.
DOI : 10.1016/j.jpainsymman.2008.04.006

D. Farge, P. Debourdeau, and N. Gorin, Long-Term Use of Low-Molecular-Weight Heparins (LMWH) for Cancer-Associated Venous Thromboembolism (VTE): Patients' Perception in Tropique, a Prospective, Multicenter, Observational Study Clinically Relevant

L. Sheard, H. Prout, and D. Dowding, Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: A qualitative study, Palliative Medicine, vol.27, issue.6, pp.339-387, 2013.
DOI : 10.4324/9780203413081_chapter_9

K. Kierner, V. Gartner, and M. Schwarz, Use of Thromboprophylaxis in Palliative Care Patients: A Survey Among Experts in Palliative Care, Oncology, Intensive Care, and Anticoagulation, American Journal of Hospice and Palliative Medicine, vol.25, issue.2, pp.127-158, 2008.
DOI : 10.1177/1049909107310142

S. Noble and I. Finlay, Have Palliative Care Teams' Attitudes Toward Venous Thromboembolism Changed? A Survey of Thromboprophylaxis Practice Across British Specialist Palliative Care Units in the Years 2000 and 2005, Journal of Pain and Symptom Management, vol.32, issue.1, pp.38-43, 2000.
DOI : 10.1016/j.jpainsymman.2005.11.013

J. Grimshaw, L. Shirran, and R. Thomas, Changing Provider Behavior, Medical Care, vol.39, issue.2, pp.2-45, 2001.
DOI : 10.1097/00005650-200108002-00002

N. Kucher, S. Koo, and R. Quiroz, Electronic Alerts to Prevent Venous Thromboembolism among Hospitalized Patients, New England Journal of Medicine, vol.352, issue.10, pp.969-977, 2005.
DOI : 10.1056/NEJMoa041533

G. D. Candelario, C. W. Francis, and R. Panzer, A Computerized Prompt for Thromboprophylaxis in Hospitalized Cancer Patients, Thrombosis Research, vol.126, issue.1, pp.32-34, 2010.
DOI : 10.1016/j.thromres.2009.09.022

J. Stinnett, R. Pendleton, and L. Skordos, Venous thromboembolism prophylaxis in medically ill patients and the development of strategies to improve prophylaxis rates, American Journal of Hematology, vol.154, issue.3, pp.167-172, 2005.
DOI : 10.1002/ajh.20281

S. Cohn, A. Adekile, and V. Mahabir, Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention, Journal of Hospital Medicine, vol.1, issue.6, pp.331-338, 2006.
DOI : 10.1002/jhm.137

M. Maltoni, E. Scarpi, and C. Pittureri, Prospective Comparison of Prognostic Scores in Palliative Care Cancer Populations, The Oncologist, vol.17, issue.3, pp.446-54, 2012.
DOI : 10.1634/theoncologist.2011-0397

S. Legault, S. Tierney, and I. Sénécal, Evaluation of a Thromboprophylaxis Quality Improvement Project in a Palliative Care Unit, Journal of Pain and Symptom Management, vol.41, issue.3, pp.503-513, 2011.
DOI : 10.1016/j.jpainsymman.2010.05.014

C. Duverger, B. Tardy, and A. Richard, Traitement prophylactique de la maladie thromboembolique veineuse en soins palliatifs, La Presse M??dicale, vol.38, issue.9, pp.1235-1244, 2009.
DOI : 10.1016/j.lpm.2008.11.021

S. Noble, A. Nelson, and I. Finlay, Factors influencing hospice thromboprophylaxis policy: a qualitative study, Palliative Medicine, vol.478, issue.7, pp.808-821, 2008.
DOI : 10.1177/0269216308096723

L. Sheard, H. Prout, and D. Dowling, The ethical decisions UK doctors make regarding advanced cancer patients at the end of life - the perceived (in) appropriateness of anticoagulation for venous thromboembolism: A qualitative study, BMC Medical Ethics, vol.19, issue.6, p.22, 2012.
DOI : 10.1191/0269216305pm1008oa

O. Havig, Deep vein thrombosis and pulmonary embolism ? an autopsy study with multiple regression analysis of possible risk factors, Acta Chir Scand, vol.478, pp.1-120, 1977.